A prospective, multicenter phase II trial of low-dose erlotinib monotherapy for patients with previously treated non-small cell lung cancer (NSCLC) with activating mutation of epidermal growth factor receptor (EGFR): Thoracic Oncology Research Group (TORG) 0911.
Yoshiro Nakahara
Honoraria - Chugai Pharma
Yukio Hosomi
Honoraria - Chugai Pharma
Kazuhiko Yamada
No relevant relationships to disclose
Hiroaki Okamoto
No relevant relationships to disclose
Terufumi Kato
Honoraria - Chugai Pharma
Yuko Komase
No relevant relationships to disclose
Masanori Nishikawa
No relevant relationships to disclose
Satoshi Morita
Honoraria - Chugai Pharma
Hideo Kunitoh
Honoraria - AstraZeneca; Chugai Pharma
Research Funding - AstraZeneca
Koshiro Watanabe
No relevant relationships to disclose